Self-screen, the company for innovative screening and diagnostic assays

Medical and health care urgency

• Every year over 300.000 women around the world are dying unnecessary from cervical cancer.

Cervical cancer develops from a persistent HPV-infection. Cervical cancer is the fourth common cancer in women. In 2018, an estimated 570.000 women were diagnosed with the disease worldwide and about 311.000 died from the disease. However, cervical cancer can be effectively prevented by prophylactic HPV Vaccination and cervical screening.

Self-screen solution

• Self-Screen offers the best possible molecular tests to identify the women at risk for cervical cancer and its precursor lesions.

• Subsequently Self-screen’s assays can identify the women with progressing premalignant lesions or early stage cancer in need of treatment.

When early diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively. Self-screen offers the best-in-class HPV-screenings tests and in addition, a molecular follow up test based on epigenetic markers, that identifies women with progressing premalignant lesions in need of treatment.

OUR AIM

• Helping health care institutes and treating clinicians to detect cervical cancer or premalignant stages in order to provide all women worldwide with the best prevention solution.

Self-screen develops and validates the best possible tests that help women, clinicians and health care institutes to improve and optimize screening strategies. This involves the increase in participation by self-sampling methodologies, accurate detection of clinically meaningful HPV infections, and novel tests for HPV-positive women to accurately differentiate women who are in need of direct treatment, thereby reducing overtreatment of women with non-progressing disease.